[S02DA03, antipyrine, Antipyrine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[B01AD01, streptokinase, The risk or severity of bleeding can be increased when Streptokinase is combined with Cisplatin.]
[J01GA01, streptomycin, Cisplatin may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cisplatin.]
[L01AD04, streptozocin, The risk or severity of adverse effects can be increased when Streptozocin is combined with Cisplatin.]
[L04AA27, fingolimod, Cisplatin may increase the immunosuppressive activities of Fingolimod.]
[M03AB01, succinylcholine, The metabolism of Succinylcholine can be decreased when combined with Cisplatin.]
[A02BX02, sucralfate, Sucralfate may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J01CG01, sulbactam, Sulbactam may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J01EC02, sulfadiazine, Sulfadiazine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J01EC01, sulfamethoxazole, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Cisplatin.]
[M04AB02, sulfinpyrazone, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Cisplatin.]
[M01AB02, sulindac, Sulindac may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[M01AX04, apazone, Azapropazone may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Cisplatin is combined with Mercaptopurine.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Cisplatin.]
[N05CD07, temazepam, Temazepam may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L01CB02, teniposide, The risk or severity of adverse effects can be increased when Teniposide is combined with Cisplatin.]
[R03CC03, terbutaline, Terbutaline may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[B01AE07, dabigatran etexilate, Dabigatran etexilate may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[G03BA03, testosterone, Testosterone may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Tetracaine.]
[S03AA02, tetracycline, Tetracycline may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N04BC07, apomorphine, The metabolism of Apomorphine can be decreased when combined with Cisplatin.]
[L04AX02, thalidomide, The risk or severity of peripheral neuropathy can be increased when Thalidomide is combined with Cisplatin.]
[R03DA07, theobromine, Theobromine may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CA02, thiabendazole, Thiabendazole may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[A11DA01, thiamine, The serum concentration of Cisplatin can be increased when it is combined with Thiamine.]
[L01XX41, eribulin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Eribulin.]
[R06AD03, thiethylperazine, Thiethylperazine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L01AC01, thiotepa, The risk or severity of adverse effects can be increased when Cisplatin is combined with Thiotepa.]
[L01BB03, thioguanine, The risk or severity of adverse effects can be increased when Tioguanine is combined with Cisplatin.]
[N05CA19, thiopental, The therapeutic efficacy of Thiopental can be decreased when used in combination with Cisplatin.]
[G04BE06, moxisylyte, Moxisylyte may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N05AL03, tiapride, Tiapride may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[B01AC05, ticlopidine, Ticlopidine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[S01ED01, timolol, Timolol may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[P01AB02, tinidazole, Tinidazole may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[S01AA12, tobramycin, Cisplatin may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, Tolazamide may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[V04CA01, tolbutamide, Tolbutamide may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[M02AA21, tolmetin, Tolmetin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N02AX02, tramadol, Tramadol may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C01DX11, trapidil, The risk or severity of bleeding can be increased when Trapidil is combined with Cisplatin.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Tretinoin.]
[S01BA05, triamcinolone, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Triamcinolone.]
[C03DB02, triamterene, Triamterene may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N05CD05, triazolam, Triazolam may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C03AA06, trichlormethiazide, Trichlormethiazide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[A03AB12, mepenzolate, The therapeutic efficacy of Mepenzolate can be decreased when used in combination with Cisplatin.]
[A16AX12, trientine, Triethylenetetramine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[S01AD02, trifluridine, The risk or severity of adverse effects can be increased when Trifluridine is combined with Cisplatin.]
[N05AA05, triflupromazine, The therapeutic efficacy of Triflupromazine can be decreased when used in combination with Cisplatin.]
[D07AC02, fluclorolone, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Fluclorolone.]
[N04AA01, trihexyphenidyl, The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Cisplatin.]
[R03BA07, mometasone, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Mometasone.]
[A03AA05, trimebutine, Trimebutine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C02BA01, trimethaphan, Cisplatin may increase the neuromuscular blocking activities of Trimethaphan.]
[J01EA01, trimethoprim, The serum concentration of Cisplatin can be increased when it is combined with Trimethoprim.]
[A03BB01, butylscopolamine, The therapeutic efficacy of Butylscopolamine can be decreased when used in combination with Cisplatin.]
[M03AA02, tubocurarine, Cisplatin may increase the neuromuscular blocking activities of Tubocurarine.]
[R03DX07, roflumilast, Roflumilast may increase the immunosuppressive activities of Cisplatin.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Cisplatin is combined with Belimumab.]
[L01FX04, ipilimumab, Ipilimumab may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L01EX04, vandetanib, The serum concentration of Cisplatin can be increased when it is combined with Vandetanib.]
[R02AA14, oxyquinoline, Oxyquinoline may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[A10BH05, linagliptin, The serum concentration of Cisplatin can be increased when it is combined with Linagliptin.]
[B01AD04, urokinase, The risk or severity of bleeding can be increased when Urokinase is combined with Cisplatin.]
[S01AA28, vancomycin, Vancomycin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L04AA28, belatacept, The risk or severity of adverse effects can be increased when Cisplatin is combined with Belatacept.]
[N03AX21, ezogabine, Ezogabine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[B01AF01, rivaroxaban, Rivaroxaban may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[B01AC24, ticagrelor, The risk or severity of bleeding can be increased when Ticagrelor is combined with Cisplatin.]
[C08DA01, verapamil, Verapamil may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AX09, viloxazine, Viloxazine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L01CA01, vinblastine, The risk or severity of adverse effects can be increased when Cisplatin is combined with Vinblastine.]
[L01CA02, vincristine, The risk or severity of adverse effects can be increased when Cisplatin is combined with Vincristine.]
[L01CA03, vindesine, The risk or severity of adverse effects can be increased when Vindesine is combined with Cisplatin.]
[B03BA01, vitamin B12, The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Cisplatin.]
[B01AA03, warfarin, Cisplatin may decrease the excretion rate of Warfarin which could result in a higher serum level.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF01, zidovudine, The risk or severity of adverse effects can be increased when Zidovudine is combined with Cisplatin.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L01FX05, brentuximab vedotin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Brentuximab vedotin.]
[M05BA05, tiludronic acid, Tiludronic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[B06AC02, icatibant, Icatibant may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L01ED01, crizotinib, The serum concentration of Cisplatin can be increased when it is combined with Crizotinib.]
[B01AE01, desirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Cisplatin.]
[A02BC04, rabeprazole, Rabeprazole may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[M05BA06, ibandronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cisplatin is combined with Ibandronate.]
[N05AE04, ziprasidone, The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Cisplatin.]
[G03AC10, drospirenone, Drospirenone may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AC02, deferiprone, Deferiprone may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cisplatin.]
[N02BA01, aspirin, Acetylsalicylic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L01EJ01, ruxolitinib, The risk or severity of adverse effects can be increased when Cisplatin is combined with Ruxolitinib.]
[G04BD07, tolterodine, Tolterodine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J01DH04, doripenem, Doripenem may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C07AB03, atenolol, Cisplatin may increase the bradycardic activities of Atenolol.]
[L03AB11, peginterferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Cisplatin.]
[L01FA01, rituximab, Rituximab may increase the nephrotoxic activities of Cisplatin.]
[M03AC04, atracurium, The therapeutic efficacy of Atracurium can be decreased when used in combination with Cisplatin.]
[S01FA01, atropine, The therapeutic efficacy of Atropine can be decreased when used in combination with Cisplatin.]
[M01CB03, auranofin, Auranofin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[H02AB11, prednylidene, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Prednylidene.]
[B03XA04, peginesatide, Peginesatide may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L01BC07, azacitidine, The risk or severity of adverse effects can be increased when Cisplatin is combined with Azacitidine.]
[L04AX01, azathioprine, The risk or severity of adverse effects can be increased when Cisplatin is combined with Azathioprine.]
[L01BC05, gemcitabine, The risk or severity of adverse effects can be increased when Gemcitabine is combined with Cisplatin.]
[J01DF01, aztreonam, Aztreonam may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[M03BX01, baclofen, Cisplatin may decrease the excretion rate of Baclofen which could result in a higher serum level.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Cisplatin.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cisplatin.]
[L01FD02, pertuzumab, The risk or severity of cardiotoxicity can be increased when Cisplatin is combined with Pertuzumab.]
[A08AA11, lorcaserin, Lorcaserin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[G04BD12, mirabegron, Mirabegron may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L01XG02, carfilzomib, The risk or severity of adverse effects can be increased when Cisplatin is combined with Carfilzomib.]
[L02BB04, enzalutamide, Enzalutamide may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L01EA04, bosutinib, The risk or severity of adverse effects can be increased when Cisplatin is combined with Bosutinib.]
[L04AA31, teriflunomide, The risk or severity of adverse effects can be increased when Cisplatin is combined with Teriflunomide.]
[B01AX01, defibrotide, The risk or severity of bleeding can be increased when Defibrotide is combined with Cisplatin.]
[L04AA22, abetimus, The risk or severity of adverse effects can be increased when Cisplatin is combined with Abetimus.]
[H02AA01, aldosterone, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Aldosterone.]
[N05CA04, barbital, The therapeutic efficacy of Barbital can be decreased when used in combination with Cisplatin.]
[C01AA01, acetyldigitoxin, Acetyldigitoxin may decrease the cardiotoxic activities of Cisplatin.]
[D02BA02, octinoxate, Octinoxate may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L01AA09, bendamustine, The risk or severity of adverse effects can be increased when Cisplatin is combined with Bendamustine.]
[N04BD02, rasagiline, Rasagiline may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N03AX22, perampanel, The metabolism of Perampanel can be decreased when combined with Cisplatin.]
[L04AA29, tofacitinib, Cisplatin may increase the immunosuppressive activities of Tofacitinib.]
[R06AC06, thonzylamine, The therapeutic efficacy of Thonzylamine can be decreased when used in combination with Cisplatin.]
[G04BD10, darifenacin, The therapeutic efficacy of Darifenacin can be decreased when used in combination with Cisplatin.]
[V09IX04, fluorodeoxyglucose F18, Fludeoxyglucose (18F) may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[V08CA11, gadofosveset, Gadofosveset trisodium may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L01EA05, ponatinib, The risk or severity of adverse effects can be increased when Cisplatin is combined with Ponatinib.]
[B01AF02, apixaban, The risk or severity of bleeding can be increased when Apixaban is combined with Cisplatin.]
[A16AX08, teduglutide, Teduglutide may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[A10BH04, alogliptin, Alogliptin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[A16AX09, glycerol phenylbutyrate, Glycerol phenylbutyrate may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C03AA01, bendroflumethiazide, Bendroflumethiazide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Cisplatin is combined with Pomalidomide.]
[G03XC05, ospemifene, The metabolism of Ospemifene can be decreased when combined with Cisplatin.]
[N02BA10, benorilate, Benorilate may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[A10BK02, canagliflozin, Canagliflozin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L04AX07, dimethyl fumarate, The risk or severity of adverse effects can be increased when Cisplatin is combined with Dimethyl fumarate.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Benzocaine.]
[L03AA12, ancestim, Ancestim may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[M01AH01, celecoxib, Celecoxib may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L04AA18, everolimus, The risk or severity of adverse effects can be increased when Cisplatin is combined with Everolimus.]
[N04AC01, benztropine, Benzatropine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L01EC02, dabrafenib, The serum concentration of Cisplatin can be increased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, Benzydamine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L01EE01, trametinib, Trametinib may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Benzyl alcohol.]
[V09AX05, florbetapir F-18, Florbetapir (18F) may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AX28, levomilnacipran, Levomilnacipran may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J05AJ03, dolutegravir, The serum concentration of Cisplatin can be increased when it is combined with Dolutegravir.]
[L03AA14, lipegfilgrastim, Cisplatin may increase the myelosuppressive activities of Lipegfilgrastim.]
[A10BJ03, lixisenatide, Lixisenatide may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C02KX04, macitentan, Macitentan may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L01EL01, ibrutinib, The risk or severity of adverse effects can be increased when Cisplatin is combined with Ibrutinib.]
[N06AX26, vortioxetine, Vortioxetine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[G03AC08, etonogestrel, Etonogestrel may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J05AP08, sofosbuvir, Sofosbuvir may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[A10BK01, dapagliflozin, Dapagliflozin may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA27, droxidopa, Droxidopa may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C07AB04, acebutolol, Cisplatin may increase the bradycardic activities of Acebutolol.]
[N05CH03, tasimelteon, Tasimelteon may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L04AA32, apremilast, The risk or severity of adverse effects can be increased when Cisplatin is combined with Apremilast.]
[L02BG02, formestane, Formestane may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[S03BA03, betamethasone, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Betamethasone.]
[S01ED02, betaxolol, Cisplatin may increase the bradycardic activities of Betaxolol.]
[B01AE03, argatroban, The risk or severity of bleeding can be increased when Argatroban is combined with Cisplatin.]
[V03AB34, fomepizole, Fomepizole may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L04AC11, siltuximab, The risk or severity of adverse effects can be increased when Cisplatin is combined with Siltuximab.]
[B01AC26, vorapaxar, The risk or severity of bleeding can be increased when Vorapaxar is combined with Cisplatin.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Cisplatin is combined with Vedolizumab.]
[A03BA03, hyoscyamine, The therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Cisplatin.]
[B01AA07, acenocoumarol, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Cisplatin.]
[L01XH04, belinostat, The risk or severity of adverse effects can be increased when Cisplatin is combined with Belinostat.]
[L01EM01, idelalisib, The risk or severity of adverse effects can be increased when Cisplatin is combined with Idelalisib.]
[L03AB13, peginterferon beta-1a, The risk or severity of adverse effects can be increased when Cisplatin is combined with Peginterferon beta-1a.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[D11AA01, glycopyrronium, The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Cisplatin.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[V04CX03, methacholine, The risk or severity of adverse effects can be increased when Cisplatin is combined with Methacholine.]
[L01BC08, decitabine, The risk or severity of adverse effects can be increased when Cisplatin is combined with Decitabine.]
[N04AA02, biperiden, The therapeutic efficacy of Biperiden can be decreased when used in combination with Cisplatin.]
[L04AX05, pirfenidone, The risk or severity of adverse effects can be increased when Cisplatin is combined with Pirfenidone.]
[S03AA06, gentamicin, The serum concentration of Gentamicin can be increased when it is combined with Cisplatin.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Cisplatin is combined with Blinatumomab.]
[L01XK01, olaparib, The risk or severity of adverse effects can be increased when Cisplatin is combined with Olaparib.]
[B01AA01, dicumarol, The risk or severity of bleeding can be increased when Dicoumarol is combined with Cisplatin.]
[B01AF03, edoxaban, Edoxaban may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L04AC10, secukinumab, The risk or severity of adverse effects can be increased when Cisplatin is combined with Secukinumab.]
[L01EF01, palbociclib, The risk or severity of adverse effects can be increased when Cisplatin is combined with Palbociclib.]
[L01EX08, lenvatinib, The serum concentration of Cisplatin can be increased when it is combined with Lenvatinib.]
[L01XH03, panobinostat, The risk or severity of adverse effects can be increased when Cisplatin is combined with Panobinostat.]
[N02BE01, acetaminophen, Acetaminophen may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L01DC01, bleomycin, The risk or severity of adverse effects can be increased when Bleomycin is combined with Cisplatin.]
[A03AA09, difemerine, The therapeutic efficacy of Difemerine can be decreased when used in combination with Cisplatin.]
[B01AA11, tioclomarol, The risk or severity of bleeding can be increased when Tioclomarol is combined with Cisplatin.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J05AP06, asunaprevir, The metabolism of Asunaprevir can be decreased when combined with Cisplatin.]
[B01AC25, cangrelor, The risk or severity of bleeding can be increased when Cangrelor is combined with Cisplatin.]
[M02AA25, aceclofenac, Aceclofenac may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[M01AB11, acemetacin, Acemetacin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[S01EC01, acetazolamide, Acetazolamide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB37, idarucizumab, Idarucizumab may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L01CX01, trabectedin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Trabectedin.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Cisplatin is combined with Mepolizumab.]
[J02AC05, isavuconazole, The serum concentration of Cisplatin can be increased when it is combined with Isavuconazole.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Cisplatin.]
[L01XG03, ixazomib, Ixazomib may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[M04AB05, lesinurad, Lesinurad may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N05CA05, aprobarbital, The therapeutic efficacy of Aprobarbital can be decreased when used in combination with Cisplatin.]
[M01AE16, alminoprofen, Alminoprofen may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N03AX23, brivaracetam, Brivaracetam may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Cisplatin is combined with Ixekizumab.]
[N05BA08, bromazepam, Bromazepam may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[A02AD05, aluminum magnesium silicate, Almasilate may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[R06AB01, brompheniramine, The metabolism of Brompheniramine can be decreased when combined with Cisplatin.]
[C03CA02, bumetanide, The risk or severity of ototoxicity and nephrotoxicity can be increased when Bumetanide is combined with Cisplatin.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Bupivacaine.]
[C07AA19, bupranolol, Cisplatin may increase the bradycardic activities of Bupranolol.]
[N05BE01, buspirone, Buspirone may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L01AB01, busulfan, The risk or severity of adverse effects can be increased when Cisplatin is combined with Busulfan.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Cisplatin is combined with Arsenic trioxide.]
[P01BE02, artemether, The metabolism of Artemether can be decreased when combined with Cisplatin.]
[M02AA03, clofezone, Rabeprazole may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Cisplatin is combined with Brodalumab.]
[A07EC04, balsalazide, Balsalazide may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[R03CC12, bambuterol, Cisplatin may increase the neuromuscular blocking activities of Bambuterol.]
[L04AA36, ocrelizumab, Ocrelizumab may increase the immunosuppressive activities of Cisplatin.]
[A06AH05, naldemedine, Naldemedine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N07XX16, deutetrabenazine, Deutetrabenazine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N02BF02, pregabalin, Pregabalin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Oxybuprocaine.]
[R05DB01, benzonatate, Cisplatin may increase the neuromuscular blocking activities of Benzonatate.]
[P01CA02, benznidazole, Benznidazole may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Cisplatin.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Cisplatin is combined with Linezolid.]
[J05AF06, abacavir, Abacavir may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N07XX13, valbenazine, Valbenazine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L04AB02, infliximab, The risk or severity of adverse effects can be increased when Infliximab is combined with Cisplatin.]
[L04AC14, sarilumab, The risk or severity of adverse effects can be increased when Cisplatin is combined with Sarilumab.]
[N07AB02, bethanechol, The risk or severity of adverse effects can be increased when Cisplatin is combined with Bethanechol.]
[J01MA23, delafloxacin, Delafloxacin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[B01AF04, betrixaban, The risk or severity of bleeding can be increased when Betrixaban is combined with Cisplatin.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Cisplatin is combined with Guselkumab.]
[S01EB09, acetylcholine, The risk or severity of adverse effects can be increased when Cisplatin is combined with Acetylcholine.]
[L01BC06, capecitabine, The risk or severity of adverse effects can be increased when Cisplatin is combined with Capecitabine.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Cisplatin.]
[L01XH01, vorinostat, The risk or severity of adverse effects can be increased when Cisplatin is combined with Vorinostat.]
[C07AB07, bisoprolol, Bisoprolol may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J05AG03, efavirenz, The metabolism of Efavirenz can be decreased when combined with Cisplatin.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C07AA17, bopindolol, Cisplatin may increase the bradycardic activities of Bopindolol.]
[N04AA11, bornaprine, The therapeutic efficacy of Bornaprine can be decreased when used in combination with Cisplatin.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Cisplatin.]
[L01BA03, raltitrexed, The risk or severity of adverse effects can be increased when Raltitrexed is combined with Cisplatin.]
[V03AF08, palifermin, The therapeutic efficacy of Palifermin can be decreased when used in combination with Cisplatin.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Budesonide.]
[C04AX20, buflomedil, The risk or severity of bleeding can be increased when Buflomedil is combined with Cisplatin.]
[M01AB07, bumadizone, Bumadizone may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N05CA03, butobarbital, The therapeutic efficacy of Butobarbital can be decreased when used in combination with Cisplatin.]
[C01AA02, acetyldigoxins, Acetyldigoxin may decrease the cardiotoxic activities of Cisplatin.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Capsaicin.]
[A10BK04, ertugliflozin, Ertugliflozin may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AX18, acrivastine, Acrivastine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[S01EB02, carbachol, The risk or severity of adverse effects can be increased when Cisplatin is combined with Carbamoylcholine.]
[L02BB05, apalutamide, The serum concentration of Cisplatin can be increased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, The risk or severity of adverse effects can be increased when Cisplatin is combined with Carbamazepine.]
[A03AA03, camylofine, The therapeutic efficacy of Camylofin can be decreased when used in combination with Cisplatin.]
[L03AB06, interferon alfa-n1, The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Cisplatin.]
[C07AG02, carvedilol, Cisplatin may increase the bradycardic activities of Carvedilol.]
[L04AA37, baricitinib, The risk or severity of adverse effects can be increased when Cisplatin is combined with Baricitinib.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J01GB14, plazomicin, Cisplatin may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, Cisplatin may increase the bradycardic activities of Celiprolol.]
[P01BA07, tafenoquine, The serum concentration of Cisplatin can be increased when it is combined with Tafenoquine.]
[A16AX14, migalastat, Migalastat may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N03AX17, stiripentol, Stiripentol may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[S01GX12, cetirizine, Cetirizine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Chloroprocaine.]
[D08AE05, chloroxylenol, Chloroxylenol may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[R06AA06, chlorphenoxamine, The therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Cisplatin.]
[M01AC05, lornoxicam, Lornoxicam may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N07XX15, inotersen, Inotersen may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[R03BB08, revefenacin, The therapeutic efficacy of Revefenacin can be decreased when used in combination with Cisplatin.]
[L04AA39, emapalumab, The risk or severity of adverse effects can be increased when Cisplatin is combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of adverse effects can be increased when Carmustine is combined with Cisplatin.]
[N07XX05, amifampridine, The risk or severity of adverse effects can be increased when Cisplatin is combined with Amifampridine.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Cisplatin is combined with Ravulizumab.]
[A06AX05, prucalopride, Prucalopride may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[B01AX07, caplacizumab, The risk or severity of bleeding can be increased when Caplacizumab is combined with Cisplatin.]
[B01AC23, cilostazol, Cilostazol may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AX27, esketamine, The metabolism of Esketamine can be decreased when combined with Cisplatin.]
[L04AA42, siponimod, The risk or severity of adverse effects can be increased when Cisplatin is combined with Siponimod.]
[N06BA14, solriamfetol, Solriamfetol may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L01EN01, erdafitinib, The serum concentration of Cisplatin can be increased when it is combined with Erdafitinib.]
[N05BA09, clobazam, Clobazam may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[H02AB14, cloprednol, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Cloprednol.]
[L04AB01, etanercept, The risk or severity of adverse effects can be increased when Etanercept is combined with Cisplatin.]
[H02AB17, cortivazol, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Cortivazol.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Cisplatin is combined with Risankizumab.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C03BX03, cicletanine, Cicletanine may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L04AA44, upadacitinib, The risk or severity of adverse effects can be increased when Cisplatin is combined with Upadacitinib.]
[N07XX11, pitolisant, Pitolisant may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Cisplatin.]
[C03AA09, cyclothiazide, Cyclothiazide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[J01XX09, daptomycin, Daptomycin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J01DB01, cephalexin, Cephalexin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J01DB09, cephradine, Cefradine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[H02AB13, deflazacort, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Deflazacort.]
[L01FD01, trastuzumab, Trastuzumab may increase the neutropenic activities of Cisplatin.]
[L01FD03, ado-trastuzumab emtansine, The risk or severity of adverse effects can be increased when Cisplatin is combined with Trastuzumab emtansine.]
[L04AX09, diroximel fumarate, The risk or severity of adverse effects can be increased when Cisplatin is combined with Diroximel fumarate.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be decreased when combined with Cisplatin.]
[B06AX03, voxelotor, The metabolism of Voxelotor can be decreased when combined with Cisplatin.]
[N03AX25, cenobamate, The metabolism of Cenobamate can be decreased when combined with Cisplatin.]
[A16AX16, givosiran, Givosiran may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[M09AX08, golodirsen, Golodirsen may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[S01XA12, dexpanthenol, Dexpanthenol may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L04AA53, teprotumumab, The risk or severity of adverse effects can be increased when Cisplatin is combined with Teprotumumab.]
[H02CA02, osilodrostat, The metabolism of Osilodrostat can be decreased when combined with Cisplatin.]
[L04AA38, ozanimod, The risk or severity of adverse effects can be increased when Cisplatin is combined with Ozanimod.]
[R02AA03, dichlorobenzyl alcohol, Dichlorobenzyl alcohol may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[G03DB08, dienogest, Dienogest may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[M01AH02, rofecoxib, Rofecoxib may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L01XF03, bexarotene, The risk or severity of adverse effects can be increased when Bexarotene is combined with Cisplatin.]
[C08CA16, clevidipine, Clevidipine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C01BD07, dronedarone, The serum concentration of Cisplatin can be increased when it is combined with Dronedarone.]
[L01AA02, chlorambucil, The risk or severity of adverse effects can be increased when Chlorambucil is combined with Cisplatin.]
[S03AA08, chloramphenicol, The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Cisplatin.]
[L01EH03, tucatinib, The serum concentration of Cisplatin can be increased when it is combined with Tucatinib.]
[A03AA08, dihexyverine, The therapeutic efficacy of Dihexyverine can be decreased when used in combination with Cisplatin.]
[D07XB03, fluprednidene, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Fluprednidene.]
[P01BE01, artemisinin, The metabolism of Artemisinin can be decreased when combined with Cisplatin.]
[G04BD09, trospium, The therapeutic efficacy of Trospium can be decreased when used in combination with Cisplatin.]
[M01AC04, droxicam, Droxicam may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[V08CA05, mangafodipir, Mangafodipir may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[B01AE02, lepirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Cisplatin.]
[M02AA27, dexketoprofen, Dexketoprofen may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N05CM02, chlormethiazole, The metabolism of Clomethiazole can be decreased when combined with Cisplatin.]
[L04AA47, inebilizumab, The risk or severity of infection can be increased when Cisplatin is combined with Inebilizumab.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Dyclonine.]
[R05CB11, stepronin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Stepronin.]
[L04AC19, satralizumab, The risk or severity of adverse effects can be increased when Cisplatin is combined with Satralizumab.]
[P01BA01, chloroquine, Chloroquine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C03AA04, chlorothiazide, Chlorothiazide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AB04, chlorpheniramine, The serum concentration of Cisplatin can be increased when it is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, Chlorpromazine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[A10BB02, chlorpropamide, Chlorpropamide may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N05AF03, chlorprothixene, The therapeutic efficacy of Chlorprothixene can be decreased when used in combination with Cisplatin.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BB03, chlorzoxazone, Chlorzoxazone may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N02BA07, ethenzamide, Ethenzamide may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N02BA03, choline salicylate, The serum concentration of Cisplatin can be increased when it is combined with Choline salicylate.]
[M01AB08, etodolac, Etodolac may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[M02AA06, etofenamate, Etofenamate may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L01BB05, fludarabine, The risk or severity of adverse effects can be increased when Cisplatin is combined with Fludarabine.]
[M01AX25, chondroitin sulfates, Chondroitin sulfate may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L04AD03, voclosporin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Voclosporin.]
[V03AF12, trilaciclib, The risk or severity of nephrotoxicity can be increased when Trilaciclib is combined with Cisplatin.]
[M01AE05, fenbufen, Fenbufen may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C01CA19, fenoldopam, Fenoldopam may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J01DD15, cefdinir, Cefdinir may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[R03BA03, flunisolide, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Flunisolide.]
[N02BG07, flupirtine, Flupirtine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L04AA50, ponesimod, The risk or severity of adverse effects can be increased when Cisplatin is combined with Ponesimod.]
[S01LA08, bevacizumab, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Cisplatin.]
[L03AB10, peginterferon alfa-2b, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Cisplatin.]
[A02BA01, cimetidine, The serum concentration of Cisplatin can be increased when it is combined with Cimetidine.]
[V08CA04, gadoteridol, Gadoteridol may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N07CA02, cinnarizine, The metabolism of Cinnarizine can be decreased when combined with Cisplatin.]
[S03AA07, ciprofloxacin, Ciprofloxacin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Cisplatin is combined with Antilymphocyte immunoglobulin (horse).]
[S02BA08, fluocinolone acetonide, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Fluocinolone acetonide.]
[L04AA54, pegcetacoplan, The risk or severity of adverse effects can be increased when Cisplatin is combined with Pegcetacoplan.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AA48, belumosudil, The risk or severity of adverse effects can be increased when Cisplatin is combined with Belumosudil.]
[P01CA03, fexinidazole, The serum concentration of Cisplatin can be increased when it is combined with Fexinidazole.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Cisplatin is combined with Anifrolumab.]
[M01AG01, mefenamic acid, Mefenamic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of adverse effects can be increased when Cisplatin is combined with Ropeginterferon alfa-2b.]
[B01AD11, tenecteplase, The risk or severity of bleeding can be increased when Tenecteplase is combined with Cisplatin.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Levobupivacaine.]
[N06AA04, clomipramine, Clomipramine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N03AE01, clonazepam, Clonazepam may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Cisplatin is combined with Spesolimab.]
[L04AA56, deucravacitinib, The risk or severity of adverse effects can be increased when Cisplatin is combined with Deucravacitinib.]
[N05BA21, clotiazepam, The metabolism of Clotiazepam can be decreased when combined with Cisplatin.]
[N05AH02, clozapine, The risk or severity of neutropenia can be increased when Cisplatin is combined with Clozapine.]
[J01GB12, arbekacin, Cisplatin may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Cocaine.]
[L04AC21, bimekizumab, The risk or severity of adverse effects can be increased when Cisplatin is combined with Bimekizumab.]
[M01AX13, proquazone, Proquazone may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[M03AC05, hexafluorenium, The therapeutic efficacy of Hexafluronium can be decreased when used in combination with Cisplatin.]
[M04AC01, colchicine, Colchicine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[A03AB10, hexocyclium, The therapeutic efficacy of Hexocyclium can be decreased when used in combination with Cisplatin.]
[A03BB06, homatropine methylbromide, The therapeutic efficacy of Homatropine methylbromide can be decreased when used in combination with Cisplatin.]
[J01XB01, colistin, Cisplatin may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L04AA13, leflunomide, The risk or severity of adverse effects can be increased when Cisplatin is combined with Leflunomide.]
[A04AA03, tropisetron, Tropisetron may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[A10BX03, nateglinide, Nateglinide may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N02BA16, imidazole-2-hydroxybenzoate, Imidazole salicylate may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L01BB07, nelarabine, The risk or severity of adverse effects can be increased when Cisplatin is combined with Nelarabine.]
[R03BA08, ciclesonide, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Ciclesonide.]
[B01AC10, indobufen, Indobufen may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[R06AX27, desloratadine, The therapeutic efficacy of Desloratadine can be decreased when used in combination with Cisplatin.]
[J05AB14, valganciclovir, Valganciclovir may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C05BB03, invert sugar, Invert sugar may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[V08AB09, iodixanol, Iodixanol may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[V08AB05, iopromide, Iopromide may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[V08AB07, ioversol, Ioversol may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[V08AB12, ioxilan, Ioxilan may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[M01AH03, valdecoxib, Valdecoxib may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C01AA06, lanatoside C, Lanatoside C may decrease the cardiotoxic activities of Cisplatin.]
[N02CC05, almotriptan, Almotriptan may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[M01AH04, parecoxib, Parecoxib may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[B01AB12, bemiparin, The risk or severity of bleeding can be increased when Bemiparin is combined with Cisplatin.]
[S01AD03, acyclovir, Acyclovir may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N05BA10, ketazolam, Ketazolam may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[M01AA06, kebuzone, Kebuzone may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L01EA01, imatinib, The risk or severity of adverse effects can be increased when Cisplatin is combined with Imatinib.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Cisplatin.]
[N03AX09, lamotrigine, The serum concentration of Cisplatin can be increased when it is combined with Lamotrigine.]
[S01BA03, cortisone, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Cortisone.]
[N07BC04, lofexidine, Lofexidine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[M01AB09, lonazolac, Lonazolac may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[M02AA31, loxoprofen, Loxoprofen may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C09AA03, lisinopril, Lisinopril may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[A06AD01, magnesium carbonate, Magnesium carbonate may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[A03AA04, mebeverine, The therapeutic efficacy of Mebeverine can be decreased when used in combination with Cisplatin.]
[C07AA14, mepindolol, Cisplatin may increase the bradycardic activities of Mepindolol.]
[H02AB15, meprednisone, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Meprednisone.]
[J01DH02, meropenem, Meropenem may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N04AA03, methixene, The therapeutic efficacy of Metixene can be decreased when used in combination with Cisplatin.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, Melperone may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L04AA15, alefacept, The risk or severity of adverse effects can be increased when Alefacept is combined with Cisplatin.]
[C03AA07, cyclopenthiazide, Cyclopenthiazide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF07, tenofovir disoproxil, Cisplatin may increase the nephrotoxic activities of Tenofovir disoproxil.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Cisplatin.]
[S01XA18, cyclosporine, Cisplatin may increase the immunosuppressive activities of Cyclosporine.]
[R06AX02, cyproheptadine, The therapeutic efficacy of Cyproheptadine can be decreased when used in combination with Cisplatin.]
[M02AA02, mofebutazone, Mofebutazone may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[M01AX22, morniflumate, Morniflumate may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C03XA02, conivaptan, Conivaptan may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Cisplatin is combined with Cytarabine.]
[M01AH05, etoricoxib, Etoricoxib may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L01AX04, dacarbazine, The risk or severity of adverse effects can be increased when Cisplatin is combined with Dacarbazine.]
[L01DA01, dactinomycin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Dactinomycin.]
[L01DB02, daunorubicin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Daunorubicin.]
[M01AX01, nabumetone, Nabumetone may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N07BB05, nalmefene, Nalmefene may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C07AB12, nebivolol, Cisplatin may increase the bradycardic activities of Nebivolol.]
[S01GX04, nedocromil, Nedocromil may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AX06, nefazodone, Nefazodone may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C01DX16, nicorandil, Nicorandil may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L02BB02, nilutamide, Nilutamide may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[M03AC11, cisatracurium, The therapeutic efficacy of Cisatracurium can be decreased when used in combination with Cisplatin.]
[B01AX05, fondaparinux, Fondaparinux may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[D11AH02, pimecrolimus, The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cisplatin.]
[N06AB10, escitalopram, The therapeutic efficacy of Escitalopram can be decreased when used in combination with Cisplatin.]
[G04BD08, solifenacin, The therapeutic efficacy of Solifenacin can be decreased when used in combination with Cisplatin.]
[A07EC03, olsalazine, Olsalazine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AA01, desipramine, The serum concentration of Cisplatin can be increased when it is combined with Desipramine.]
[C01AA07, deslanoside, Deslanoside may decrease the cardiotoxic activities of Cisplatin.]
[H01BA02, desmopressin, Desmopressin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[D07XC02, desoximetasone, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Desoximetasone.]
[H02AA03, desoxycorticosterone, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Desoxycortone.]
[J01DH03, ertapenem, Ertapenem may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L01XA03, oxaliplatin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Oxaliplatin.]
[M01AE12, oxaprozin, Oxaprozin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[S03BA01, dexamethasone, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Dexamethasone.]
[N04AA08, dexetimide, The therapeutic efficacy of Dexetimide can be decreased when used in combination with Cisplatin.]
[G04BD04, oxybutynin, The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Cisplatin.]
[A03AA01, oxyphencyclimine, The therapeutic efficacy of Oxyphencyclimine can be decreased when used in combination with Cisplatin.]
[L04AB04, adalimumab, The risk or severity of adverse effects can be increased when Adalimumab is combined with Cisplatin.]
[N06BA02, dextroamphetamine, Amphetamine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[R05DA09, dextromethorphan, The therapeutic efficacy of Dextromethorphan can be decreased when used in combination with Cisplatin.]
[N06AB05, paroxetine, The therapeutic efficacy of Paroxetine can be decreased when used in combination with Cisplatin.]
[B01AC04, clopidogrel, The serum concentration of Cisplatin can be increased when it is combined with Clopidogrel.]
[C01DA05, pentaerythritol tetranitrate, Pentaerythritol tetranitrate may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[P03AC04, permethrin, Permethrin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N05BA01, diazepam, Diazepam may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Cinchocaine.]
[R05DA08, pholcodine, Pholcodine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[M05BA02, clodronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cisplatin is combined with Clodronic acid.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, Diclofenac may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J05AD01, foscarnet, The risk or severity of nephrotoxicity can be increased when Cisplatin is combined with Foscarnet.]
[A03AA07, dicyclomine, Dicyclomine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J05AF02, didanosine, Didanosine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[A03AB14, pipenzolate, The therapeutic efficacy of Pipenzolate can be decreased when used in combination with Cisplatin.]
[L01DC04, ixabepilone, The risk or severity of adverse effects can be increased when Cisplatin is combined with Ixabepilone.]
[L01DB08, pirarubicin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Pirarubicin.]
[C03CA03, piretanide, The risk or severity of ototoxicity and nephrotoxicity can be increased when Piretanide is combined with Cisplatin.]
[C08CA03, isradipine, Isradipine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[D07XC04, diflucortolone, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Difluocortolone.]
[A03AB11, poldine, The therapeutic efficacy of Poldine can be decreased when used in combination with Cisplatin.]
[N02BA11, diflunisal, Diflunisal may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C01AA04, digitoxin, Digitoxin may decrease the cardiotoxic activities of Cisplatin.]
[C01AA05, digoxin, Cisplatin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01XX24, pegaspargase, The risk or severity of adverse effects can be increased when Pegaspargase is combined with Cisplatin.]
[N02AA03, hydromorphone, Hydromorphone may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L04AX04, lenalidomide, The risk or severity of adverse effects can be increased when Lenalidomide is combined with Cisplatin.]
[J05AE08, atazanavir, Atazanavir may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[H03BC01, potassium perchlorate, Potassium perchlorate may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[V03AB04, pralidoxime, Pralidoxime may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Pramocaine.]
[V03AB09, dimercaprol, Dimercaprol may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[R06AB03, dimethindene, The therapeutic efficacy of Dimetindene can be decreased when used in combination with Cisplatin.]
[M02AX03, dimethyl sulfoxide, Dimethyl sulfoxide may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N02BB04, propyphenazone, Propyphenazone may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[M01AB14, proglumetacin, Proglumetacin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[G02AD02, dinoprostone, The serum concentration of Cisplatin can be increased when it is combined with Dinoprostone.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Diphenhydramine.]
[B01AC07, dipyridamole, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Dipyridamole.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Cisplatin.]
[A03FA02, cisapride, The metabolism of Cisapride can be decreased when combined with Cisplatin.]
[S01XA23, sirolimus, The risk or severity of adverse effects can be increased when Cisplatin is combined with Sirolimus.]
[S01AX06, resorcinol, Resorcinol may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C01BA03, disopyramide, The serum concentration of Cisplatin can be increased when it is combined with Disopyramide.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Cisplatin is combined with Natalizumab.]
[R06AE09, levocetirizine, Levocetirizine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Cisplatin.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Ropivacaine.]
[L01EX01, sunitinib, The risk or severity of adverse effects can be increased when Cisplatin is combined with Sunitinib.]
[C03XA01, tolvaptan, Tolvaptan may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XG01, bortezomib, The risk or severity of adverse effects can be increased when Bortezomib is combined with Cisplatin.]
[G04BE08, tadalafil, Tadalafil may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[S01BC05, ketorolac, Ketorolac may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C01EB18, ranolazine, The serum concentration of Cisplatin can be increased when it is combined with Ranolazine.]
[N02BA06, salsalate, Salsalate may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[R03AC12, salmeterol, The risk or severity of hypokalemia can be increased when Cisplatin is combined with Salmeterol.]
[H05BA01, salmon calcitonin, Salmon calcitonin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C01CA07, dobutamine, Dobutamine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[A03FA03, domperidone, The metabolism of Domperidone can be decreased when combined with Cisplatin.]
[C01CA04, dopamine, The serum concentration of Cisplatin can be increased when it is combined with Dopamine.]
[N06AA16, dothiepin, The metabolism of Dosulepin can be decreased when combined with Cisplatin.]
[N06AA12, doxepin, Doxepin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L01DB01, doxorubicin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Doxorubicin.]
[J01AA02, doxycycline, Doxycycline may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[R06AA09, doxylamine, The therapeutic efficacy of Doxylamine can be decreased when used in combination with Cisplatin.]
[N01AB08, sevoflurane, The metabolism of Sevoflurane can be decreased when combined with Cisplatin.]
[A08AA10, sibutramine, Sibutramine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[A12CA02, sodium sulfate, Sodium sulfate may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[R03DA01, dyphylline, Dyphylline may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N02CC01, sumatriptan, Sumatriptan may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[V04CX07, edrophonium, Edrophonium may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C07AB13, talinolol, Cisplatin may increase the bradycardic activities of Talinolol.]
[H01AA01, corticotropin, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Corticotropin.]
[L01AX03, temozolomide, The risk or severity of adverse effects can be increased when Cisplatin is combined with Temozolomide.]
[M01AC02, tenoxicam, Tenoxicam may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C07AA16, tertatolol, Cisplatin may increase the bradycardic activities of Tertatolol.]
[G04BD01, emepronium, The therapeutic efficacy of Emepronium can be decreased when used in combination with Cisplatin.]
[M01AG02, tolfenamic acid, Tolfenamic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AG03, toloxatone, Toloxatone may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06BA09, atomoxetine, Atomoxetine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N03AX11, topiramate, Topiramate may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C03CA04, torsemide, The risk or severity of ototoxicity and nephrotoxicity can be increased when Torasemide is combined with Cisplatin.]
[A03AB08, tridihexethyl, The therapeutic efficacy of Tridihexethyl can be decreased when used in combination with Cisplatin.]
[B01AC18, triflusal, The risk or severity of bleeding can be increased when Triflusal is combined with Cisplatin.]
[H02CA01, trilostane, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Trilostane.]
[L01AA07, trofosfamide, The risk or severity of adverse effects can be increased when Cisplatin is combined with Trofosfamide.]
[N04AA12, tropatepine, The therapeutic efficacy of Tropatepine can be decreased when used in combination with Cisplatin.]
[C05CA04, troxerutin, The risk or severity of bleeding can be increased when Troxerutin is combined with Cisplatin.]
[L01CA04, vinorelbine, The risk or severity of adverse effects can be increased when Cisplatin is combined with Vinorelbine.]
[S01FB02, ephedrine, Cisplatin may increase the neuromuscular blocking activities of Ephedrine.]
[S01GX10, epinastine, The metabolism of Epinastine can be decreased when combined with Cisplatin.]
[N06AX16, venlafaxine, Venlafaxine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[S01EA01, epinephrine, The serum concentration of Cisplatin can be increased when it is combined with Epinephrine.]
[L01DB03, epirubicin, The risk or severity of adverse effects can be increased when Epirubicin is combined with Cisplatin.]
[M01AB04, zomepirac, Zomepirac may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N03AX15, zonisamide, Zonisamide may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[B01AD03, anistreplase, The risk or severity of bleeding can be increased when Anistreplase is combined with Cisplatin.]
[L01XA02, carboplatin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Carboplatin.]
[C02AC02, guanfacine, Guanfacine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[B01AC11, iloprost, The risk or severity of bleeding can be increased when Iloprost is combined with Cisplatin.]
[L03AX05, pidotimod, Pidotimod may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N05CD04, estazolam, Estazolam may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[G03CA03, estradiol, The serum concentration of Cisplatin can be increased when it is combined with Estradiol.]
[L01XX11, estramustine, The risk or severity of adverse effects can be increased when Cisplatin is combined with Estramustine.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J04AK02, ethambutol, Ethambutol may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[R03BA09, fluticasone furoate, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Fluticasone furoate.]
[R03BA05, fluticasone, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Fluticasone.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C01BD05, ibutilide, Ibutilide may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N04AA05, profenamine, The therapeutic efficacy of Profenamine can be decreased when used in combination with Cisplatin.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Meloxicam.]
[S01XA06, ethylmorphine, The metabolism of Ethylmorphine can be decreased when combined with Cisplatin.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Etidocaine.]
[N01AX07, etomidate, Etomidate may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L01CB01, etoposide, The risk or severity of adverse effects can be increased when Cisplatin is combined with Etoposide.]
[L04AD02, tacrolimus, Tacrolimus may increase the immunosuppressive activities of Cisplatin.]
[R06AX12, terfenadine, The therapeutic efficacy of Terfenadine can be decreased when used in combination with Cisplatin.]
[P01AX07, trimetrexate, Trimetrexate may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AX12, bupropion, The excretion of Cisplatin can be decreased when combined with Bupropion.]
[N06AB08, fluvoxamine, Fluvoxamine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L02AE02, leuprolide, Leuprolide may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Cisplatin.]
[M01CB01, gold sodium thiomalate, Sodium aurothiomalate may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[B05AA05, dextran, Dextran may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[V03AF02, dexrazoxane, The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Cisplatin.]
[A02BA03, famotidine, The serum concentration of Cisplatin can be increased when it is combined with Famotidine.]
[A16AA01, levocarnitine, Levocarnitine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N03AX26, fenfluramine, The metabolism of Fenfluramine can be decreased when combined with Cisplatin.]
[M01AE04, fenoprofen, Fenoprofen may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[R03CC04, fenoterol, The therapeutic efficacy of Fenoterol can be decreased when used in combination with Cisplatin.]
[N02AB03, fentanyl, Fentanyl may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[R03CC02, albuterol, Salbutamol may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[B01AD05, plasmin, The risk or severity of bleeding can be increased when Fibrinolysin is combined with Cisplatin.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Cisplatin is combined with Clofarabine.]
[L04AA40, cladribine, The risk or severity of adverse effects can be increased when Cladribine is combined with Cisplatin.]
[N07AX03, cevimeline, Cevimeline may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[G04BD02, flavoxate, Flavoxate may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N02BG04, floctafenine, Floctafenine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J02AC01, fluconazole, Fluconazole may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J02AX01, flucytosine, The risk or severity of adverse effects can be increased when Cisplatin is combined with Flucytosine.]
[H02AA02, fludrocortisone, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Fludrocortisone.]
[V03AB25, flumazenil, Flumazenil may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[D07XB01, flumethasone, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Flumethasone.]
[N05CD03, flunitrazepam, The metabolism of Flunitrazepam can be decreased when combined with Cisplatin.]
[D07AC08, fluocinonide, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Fluocinonide.]
[H02AB03, fluocortolone, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Fluocortolone.]
[L01BC09, floxuridine, The risk or severity of adverse effects can be increased when Floxuridine is combined with Cisplatin.]
[S01CB05, fluorometholone, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Fluorometholone.]
[L01BC02, fluorouracil, The risk or severity of adverse effects can be increased when Cisplatin is combined with Fluorouracil.]
[N06AB03, fluoxetine, The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Cisplatin.]
[N05AF01, flupenthixol, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Cisplatin.]
[N05CD01, flurazepam, The serum concentration of Cisplatin can be increased when it is combined with Flurazepam.]
[S01BC04, flurbiprofen, Flurbiprofen may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L02BB01, flutamide, Flutamide may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[S02AA17, fosfomycin, Fosfomycin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L01BC03, tegafur, Tegafur may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[M03AA01, alcuronium, The therapeutic efficacy of Alcuronium can be decreased when used in combination with Cisplatin.]
[C03CA01, furosemide, Furosemide may increase the nephrotoxic and ototoxic activities of Cisplatin.]
[N05CF04, eszopiclone, Eszopiclone may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[M03AC02, gallamine, The therapeutic efficacy of Gallamine can be decreased when used in combination with Cisplatin.]
[S01AD09, ganciclovir, Ganciclovir may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C10AB04, gemfibrozil, Gemfibrozil may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J01XA03, telavancin, Telavancin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L01EA02, dasatinib, The risk or severity of adverse effects can be increased when Cisplatin is combined with Dasatinib.]
[A10BB07, glipizide, Glipizide may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N05CM18, dexmedetomidine, Dexmedetomidine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C01BD04, dofetilide, The serum concentration of Dofetilide can be increased when it is combined with Cisplatin.]
[L01EX02, sorafenib, The risk or severity of adverse effects can be increased when Sorafenib is combined with Cisplatin.]
[C07AB09, esmolol, Cisplatin may increase the bradycardic activities of Esmolol.]
[M01CB04, aurothioglucose, Aurothioglucose may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[S01LA03, pegaptanib, Pegaptanib may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[B01AA12, fluindione, The risk or severity of bleeding can be increased when Fluindione is combined with Cisplatin.]
[C09AA09, fosinopril, Fosinopril may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[S01EX01, guanethidine, Guanethidine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L02AE03, goserelin, Goserelin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N05AD01, haloperidol, Haloperidol may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N01AB01, halothane, The metabolism of Halothane can be decreased when combined with Cisplatin.]
[N05AH04, quetiapine, Quetiapine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06BX13, idebenone, Idebenone may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L01CE02, irinotecan, The risk or severity of adverse effects can be increased when Cisplatin is combined with Irinotecan.]
[M04AA01, allopurinol, The risk or severity of adverse effects can be increased when Allopurinol is combined with Cisplatin.]
[S01XA14, heparin, The risk or severity of bleeding can be increased when Heparin is combined with Cisplatin.]
[G03DC01, allylestrenol, Allylestrenol may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[A07EC02, mesalamine, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cisplatin.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L01XX03, altretamine, The risk or severity of adverse effects can be increased when Altretamine is combined with Cisplatin.]
[N05CA16, hexobarbital, The therapeutic efficacy of Hexobarbital can be decreased when used in combination with Cisplatin.]
[J05AG01, nevirapine, The metabolism of Nevirapine can be decreased when combined with Cisplatin.]
[M02AA26, nimesulide, Nimesulide may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C09AA04, perindopril, Perindopril may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C02DB02, hydralazine, Hydralazine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C03AA03, hydrochlorothiazide, Hydrochlorothiazide may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[R05DA03, hydrocodone, The metabolism of Hydrocodone can be decreased when combined with Cisplatin.]
[S02BA01, hydrocortisone, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Hydrocortisone.]
[C03AA02, hydroflumethiazide, Hydroflumethiazide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA17, potassium acetate, Potassium acetate may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[G04BD06, propiverine, Propiverine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[P01BA02, hydroxychloroquine, The risk or severity of adverse effects can be increased when Cisplatin is combined with Hydroxychloroquine.]
[B05AA07, hetastarch, Hydroxyethyl Starch may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L01XX05, hydroxyurea, The risk or severity of adverse effects can be increased when Cisplatin is combined with Hydroxyurea.]
[M05BA07, risedronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cisplatin is combined with Risedronic acid.]
[R02AX02, ibuprofen, Ibuprofen may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[B05XA08, sodium acetate, Sodium acetate may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[B05CB02, sodium citrate, The risk or severity of bleeding can be increased when Sodium citrate is combined with Cisplatin.]
[L01DB06, idarubicin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Idarubicin.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be decreased when combined with Cisplatin.]
[N06AA02, imipramine, The serum concentration of Cisplatin can be increased when it is combined with Imipramine.]
[L01CD01, paclitaxel, The risk or severity of adverse effects can be increased when Cisplatin is combined with Paclitaxel.]
[R01AD07, tixocortol, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Tixocortol.]
[L01CE01, topotecan, The risk or severity of adverse effects can be increased when Cisplatin is combined with Topotecan.]
[C03BA11, indapamide, Indapamide may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[S01BC01, indomethacin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Cisplatin.]
[A11HA07, inositol, Inositol may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L03AB04, interferon alfa-2a, The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Cisplatin.]
[L03AB05, interferon alfa-2b, The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Cisplatin.]
[N06AX17, milnacipran, Milnacipran may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[A03AA30, piperidolate, The therapeutic efficacy of Piperidolate can be decreased when used in combination with Cisplatin.]
[S01XA28, varenicline, The excretion of Varenicline can be decreased when combined with Cisplatin.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Cisplatin is combined with Eculizumab.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Articaine.]
[A10BH01, sitagliptin, Sitagliptin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N05BA12, alprazolam, Alprazolam may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N05CH02, ramelteon, Ramelteon may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[R06AE01, buclizine, The therapeutic efficacy of Buclizine can be decreased when used in combination with Cisplatin.]
[L01XX35, anagrelide, The risk or severity of bleeding can be increased when Anagrelide is combined with Cisplatin.]
[C07AA01, alprenolol, Cisplatin may increase the bradycardic activities of Alprenolol.]
[C03BA02, quinethazone, Quinethazone may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[L03AB09, interferon alfacon-1, The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Cisplatin.]
[V03AB01, ipecac, Ipecac may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N01AB06, isoflurane, The metabolism of Isoflurane can be decreased when combined with Cisplatin.]
[J04AC01, isoniazid, Isoniazid may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J05AX05, inosine pranobex, Inosine pranobex may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C01DA14, isosorbide mononitrate, Isosorbide mononitrate may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[D10BA01, isotretinoin, Isotretinoin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[B01AE06, bivalirudin, The risk or severity of bleeding can be increased when Bivalirudin is combined with Cisplatin.]
[S01AA24, kanamycin, Cisplatin may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[L04AC07, tocilizumab, The risk or severity of adverse effects can be increased when Cisplatin is combined with Tocilizumab.]
[N01AX03, ketamine, Ketamine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C02KD01, ketanserin, The risk or severity of bleeding can be increased when Ketanserin is combined with Cisplatin.]
[B01AC22, prasugrel, Prasugrel may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[H02CA04, levoketoconazole, The serum concentration of Cisplatin can be increased when it is combined with Levoketoconazole.]
[N05AH03, olanzapine, The therapeutic efficacy of Olanzapine can be decreased when used in combination with Cisplatin.]
[M02AA10, ketoprofen, Ketoprofen may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L04AA24, abatacept, The risk or severity of adverse effects can be increased when Cisplatin is combined with Abatacept.]
[A16AX01, thioctic acid, The risk or severity of cytotoxicity can be decreased when Lipoic acid is combined with Cisplatin.]
[M01AE11, tiaprofenic acid, Tiaprofenic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C07AG01, labetalol, Labetalol may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N04BB01, amantadine, The serum concentration of Cisplatin can be increased when it is combined with Amantadine.]
[A06AX03, lubiprostone, Lubiprostone may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C03CC01, ethacrynic acid, The risk or severity of ototoxicity and nephrotoxicity can be increased when Etacrynic acid is combined with Cisplatin.]
[L01DC03, mitomycin, The risk or severity of adverse effects can be increased when Mitomycin is combined with Cisplatin.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Lidocaine.]
[S01AA21, amikacin, Amikacin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C03DB01, amiloride, The serum concentration of Cisplatin can be increased when it is combined with Amiloride.]
[L01AD02, lomustine, The risk or severity of adverse effects can be increased when Cisplatin is combined with Lomustine.]
[N05BA06, lorazepam, Lorazepam may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L01EG01, temsirolimus, The risk or severity of adverse effects can be increased when Cisplatin is combined with Temsirolimus.]
[B05XA11, magnesium chloride, Magnesium chloride may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Magnesium hydroxide may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L01BA05, pralatrexate, The risk or severity of adverse effects can be increased when Cisplatin is combined with Pralatrexate.]
[L01EA03, nilotinib, The risk or severity of adverse effects can be increased when Cisplatin is combined with Nilotinib.]
[V04CX04, mannitol, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cisplatin.]
[N06AA21, maprotiline, Maprotiline may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C02BB01, mecamylamine, Mecamylamine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L01AA05, mechlorethamine, The risk or severity of adverse effects can be increased when Cisplatin is combined with Mechlorethamine.]
[R06AE05, meclizine, The therapeutic efficacy of Meclizine can be decreased when used in combination with Cisplatin.]
[M02AA18, meclofenamic acid, Meclofenamic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C01AA08, medigoxin, Metildigoxin may decrease the cardiotoxic activities of Cisplatin.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AB06, nadroparin, The risk or severity of bleeding can be increased when Nadroparin is combined with Cisplatin.]
[B01AB05, enoxaparin, The risk or severity of bleeding can be increased when Enoxaparin is combined with Cisplatin.]
[B01AB04, dalteparin, The risk or severity of bleeding can be increased when Dalteparin is combined with Cisplatin.]
[L01AA03, melphalan, The risk or severity of adverse effects can be increased when Cisplatin is combined with Melphalan.]
[N06DX01, memantine, Memantine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N02AB02, meperidine, Meperidine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N03AB04, mephenytoin, The metabolism of Mephenytoin can be decreased when combined with Cisplatin.]
[N03AA01, mephobarbital, The metabolism of Methylphenobarbital can be decreased when combined with Cisplatin.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Mepivacaine.]
[G04BX16, tiopronin, Tiopronin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N05AX13, paliperidone, Paliperidone may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N07BC02, methadone, Methadone may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06BA03, methamphetamine, Metamfetamine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[A03AB07, methantheline, The therapeutic efficacy of Methantheline can be decreased when used in combination with Cisplatin.]
[J05AF05, lamivudine, Lamivudine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N03AA30, metharbital, The therapeutic efficacy of Metharbital can be decreased when used in combination with Cisplatin.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[H03BB02, methimazole, The risk or severity of adverse effects can be increased when Cisplatin is combined with Methimazole.]
[L01BA04, pemetrexed, The risk or severity of adverse effects can be increased when Cisplatin is combined with Pemetrexed.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L04AX03, methotrexate, The risk or severity of adverse effects can be increased when Cisplatin is combined with Methotrexate.]
[N05AA02, methotrimeprazine, The therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Cisplatin.]
[D05BA02, methoxsalen, Methoxsalen may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N02BG09, methoxyflurane, The metabolism of Methoxyflurane can be decreased when combined with Cisplatin.]
[C03AA08, methyclothiazide, Methyclothiazide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AB01, methyldopa, Methyldopa may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[V04CG05, methylene blue, The serum concentration of Cisplatin can be increased when it is combined with Methylene blue.]
[H02AB04, methylprednisolone, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Methylprednisolone.]
[D07AC14, methylprednisolone aceponate, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Methylprednisolone aceponate.]
[G03EK01, methyltestosterone, Methyltestosterone may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[A03FA01, metoclopramide, Metoclopramide may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C03BA08, metolazone, Metolazone may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C07AB02, metoprolol, The serum concentration of Cisplatin can be increased when it is combined with Metoprolol.]
[V04CD01, metyrapone, Metyrapone may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C01BB02, mexiletine, The metabolism of Mexiletine can be decreased when combined with Cisplatin.]
[N06AX03, mianserin, The metabolism of Mianserin can be decreased when combined with Cisplatin.]
[N02BB03, aminopyrine, Aminophenazone may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[B01AB07, parnaparin, The risk or severity of bleeding can be increased when Parnaparin is combined with Cisplatin.]
[N05CD08, midazolam, Midazolam may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[B01AB10, tinzaparin, The risk or severity of bleeding can be increased when Tinzaparin is combined with Cisplatin.]
[J05AH01, zanamivir, Zanamivir may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L01DB07, mitoxantrone, The risk or severity of adverse effects can be increased when Cisplatin is combined with Mitoxantrone.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Cisplatin.]
[C01BD01, amiodarone, The serum concentration of Cisplatin can be increased when it is combined with Amiodarone.]
[N06AA09, amitriptyline, Amitriptyline may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[A04AA05, palonosetron, Palonosetron may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L04AB05, certolizumab pegol, The risk or severity of adverse effects can be increased when Cisplatin is combined with Certolizumab pegol.]
[G04BA01, ammonium chloride, Ammonium chloride may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Cisplatin is combined with Ofatumumab.]
[L01EX03, pazopanib, The risk or severity of adverse effects can be increased when Cisplatin is combined with Pazopanib.]
[L04AA06, mycophenolic acid, The risk or severity of adverse effects can be increased when Cisplatin is combined with Mycophenolic acid.]
[M03AC03, vecuronium, The therapeutic efficacy of Vecuronium can be decreased when used in combination with Cisplatin.]
[N05CA02, amobarbital, The therapeutic efficacy of Amobarbital can be decreased when used in combination with Cisplatin.]
[N06AA17, amoxapine, The therapeutic efficacy of Amoxapine can be decreased when used in combination with Cisplatin.]
[N03AB05, fosphenytoin, Cisplatin can cause a decrease in the absorption of Fosphenytoin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L03AB08, interferon beta-1b, The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Cisplatin.]
[C07AA12, nadolol, Nadolol may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J01CA04, amoxicillin, Amoxicillin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[V03AB15, naloxone, Naloxone may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L04AC03, anakinra, The risk or severity of adverse effects can be increased when Anakinra is combined with Cisplatin.]
[N06BA01, amphetamine, Amphetamine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[M02AA12, naproxen, Naproxen may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AX21, duloxetine, Duloxetine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N04BX01, tolcapone, Tolcapone may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cisplatin.]
[L01CD02, docetaxel, The risk or severity of adverse effects can be increased when Cisplatin is combined with Docetaxel.]
[S03AA01, neomycin, The risk or severity of nephrotoxicity can be increased when Cisplatin is combined with Neomycin.]
[B01AC17, tirofiban, Tirofiban may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J02AA01, amphotericin B, Amphotericin B may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[S01AA19, ampicillin, Ampicillin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L03AX16, plerixafor, Plerixafor may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[S01AA23, netilmicin, Cisplatin may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, Desvenlafaxine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C01CE01, inamrinone, Amrinone may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L01XX01, amsacrine, The risk or severity of adverse effects can be increased when Amsacrine is combined with Cisplatin.]
[C08CA04, nicardipine, The therapeutic efficacy of Nicardipine can be decreased when used in combination with Cisplatin.]
[N07BA01, nicotine, The serum concentration of Cisplatin can be increased when it is combined with Nicotine.]
[C08CA05, nifedipine, Nifedipine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[M02AA17, niflumic acid, Niflumic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C08CA07, nisoldipine, Nisoldipine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[R07AX01, nitric oxide, Nitric Oxide may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Nitrofurantoin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N05CF03, zaleplon, Zaleplon may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N04BC05, pramipexole, Pramipexole may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C02DD01, nitroprusside, Nitroprusside may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C01CA03, norepinephrine, The serum concentration of Cisplatin can be increased when it is combined with Norepinephrine.]
[N06AA10, nortriptyline, The therapeutic efficacy of Nortriptyline can be decreased when used in combination with Cisplatin.]
[B01AC16, eptifibatide, The risk or severity of bleeding can be increased when Eptifibatide is combined with Cisplatin.]
[B01AB08, reviparin, The risk or severity of bleeding can be increased when Reviparin is combined with Cisplatin.]
[L04AC04, rilonacept, The risk or severity of adverse effects can be increased when Cisplatin is combined with Rilonacept.]
[N02AA02, opium, Opium may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[B01AD07, reteplase, The risk or severity of bleeding can be increased when Reteplase is combined with Cisplatin.]
[B01AD09, ancrod, The risk or severity of bleeding can be increased when Ancrod is combined with Cisplatin.]
[G04CA02, tamsulosin, Tamsulosin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C01AC01, ouabain, Ouabain may decrease the cardiotoxic activities of Cisplatin.]
[M05BA08, zoledronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cisplatin is combined with Zoledronic acid.]
[J01CF04, oxacillin, Oxacillin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N05BA04, oxazepam, Oxazepam may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C07AA02, oxprenolol, The serum concentration of Cisplatin can be increased when it is combined with Oxprenolol.]
[S01BC02, oxyphenbutazone, Oxyphenbutazone may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[A03AB03, oxyphenonium, The therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Cisplatin.]
[V04CH30, 4-aminohippuric acid, The serum concentration of Cisplatin can be increased when it is combined with Aminohippuric acid.]
[B01AB09, danaparoid, The risk or severity of bleeding can be increased when Danaparoid is combined with Cisplatin.]
[M03AC01, pancuronium, The therapeutic efficacy of Pancuronium can be decreased when used in combination with Cisplatin.]
[J04AB30, capreomycin, Capreomycin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[H02AB05, paramethasone, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Paramethasone.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[G04BD11, fesoterodine, Fesoterodine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C07AA23, penbutolol, Penbutolol may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[M01CC01, penicillamine, The risk or severity of adverse effects can be increased when Cisplatin is combined with Penicillamine.]
[J01CE09, penicillin G procaine, Procaine benzylpenicillin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cisplatin.]
[J07AM01, tetanus toxoid vaccine, inactivated, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cisplatin.]
[N05CA01, pentobarbital, Pentobarbital may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L01XX08, pentostatin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Pentostatin.]
[C04AD03, pentoxifylline, Pentoxifylline may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C08EX02, perhexiline, The metabolism of Perhexiline can be decreased when combined with Cisplatin.]
[J07AJ, pertussis vaccine, The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Cisplatin.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AF03, phenelzine, Phenelzine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[A10BA01, phenformin, The serum concentration of Cisplatin can be increased when it is combined with Phenformin.]
[B01AA02, phenindione, The risk or severity of bleeding can be increased when Phenindione is combined with Cisplatin.]
[N03AA02, phenobarbital, The therapeutic efficacy of Phenobarbital can be decreased when used in combination with Cisplatin.]
[C04AX02, phenoxybenzamine, The serum concentration of Cisplatin can be increased when it is combined with Phenoxybenzamine.]
[B01AA04, phenprocoumon, The risk or severity of bleeding can be increased when Phenprocoumon is combined with Cisplatin.]
[V03AB36, phentolamine, Phentolamine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[M02AA01, phenylbutazone, Phenylbutazone may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N03AB02, phenytoin, Cisplatin can cause a decrease in the absorption of Phenytoin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AB06, golimumab, The risk or severity of adverse effects can be increased when Cisplatin is combined with Golimumab.]
[S01AE05, levofloxacin, Levofloxacin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[B02BA01, vitamin K1, Phylloquinone may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[S01EB01, pilocarpine, The risk or severity of adverse effects can be increased when Cisplatin is combined with Pilocarpine.]
[C07AA03, pindolol, Pindolol may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J01CA12, piperacillin, Piperacillin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06BX03, piracetam, Piracetam may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[A02BX03, pirenzepine, The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Cisplatin.]
[S01BC06, piroxicam, Piroxicam may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J01MA11, grepafloxacin, The serum concentration of Cisplatin can be increased when it is combined with Grepafloxacin.]
[N02CX01, pizotyline, The therapeutic efficacy of Pizotifen can be decreased when used in combination with Cisplatin.]
[B01AC13, abciximab, The risk or severity of bleeding can be increased when Abciximab is combined with Cisplatin.]
[S01XA13, alteplase, The risk or severity of bleeding can be increased when Alteplase is combined with Cisplatin.]
[A10BG02, rosiglitazone, Rosiglitazone may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[L02BG03, anastrozole, The risk or severity of cardiotoxicity can be increased when Cisplatin is combined with Anastrozole.]
[L04AC08, canakinumab, The risk or severity of adverse effects can be increased when Cisplatin is combined with Canakinumab.]
[S03AA03, polymyxin B, The risk or severity of adverse effects can be increased when Cisplatin is combined with Polymyxin B.]
[C03AA05, polythiazide, Polythiazide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BH03, saxagliptin, Saxagliptin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[B05XA01, potassium chloride, Potassium chloride may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C07AB01, practolol, Cisplatin may increase the bradycardic activities of Practolol.]
[C02CA01, prazosin, The serum concentration of Prazosin can be increased when it is combined with Cisplatin.]
[S03BA02, prednisolone, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Prednisolone.]
[H02AB07, prednisone, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Prednisone.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Prilocaine.]
[N03AA03, primidone, The therapeutic efficacy of Primidone can be decreased when used in combination with Cisplatin.]
[M04AB01, probenecid, The serum concentration of Cisplatin can be increased when it is combined with Probenecid.]
[C01BA02, procainamide, The serum concentration of Procainamide can be increased when it is combined with Cisplatin.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Cisplatin is combined with Procarbazine.]
[C10AB05, fenofibrate, Fenofibrate may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N04AA04, procyclidine, The therapeutic efficacy of Procyclidine can be decreased when used in combination with Cisplatin.]
[G03DA04, progesterone, The serum concentration of Cisplatin can be increased when it is combined with Progesterone.]
[N05AA03, promazine, The therapeutic efficacy of Promazine can be decreased when used in combination with Cisplatin.]
[R06AD02, promethazine, Promethazine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C01BC03, propafenone, Cisplatin may increase the bradycardic activities of Propafenone.]
[A03AB05, propantheline, Propantheline may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N05CM06, propiomazine, The therapeutic efficacy of Propiomazine can be decreased when used in combination with Cisplatin.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be decreased when combined with Cisplatin.]
[N01AX10, propofol, The metabolism of Propofol can be decreased when combined with Cisplatin.]
[C07AA05, propranolol, The serum concentration of Cisplatin can be increased when it is combined with Propranolol.]
[H03BA02, propylthiouracil, The risk or severity of adverse effects can be increased when Cisplatin is combined with Propylthiouracil.]
[C01AB01, proscillaridin, Proscillaridin may decrease the cardiotoxic activities of Cisplatin.]
[N02CC04, rizatriptan, Rizatriptan may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[B01AC09, epoprostenol, Epoprostenol may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N05AX12, aripiprazole, The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Cisplatin.]
[N07XX07, dalfampridine, The serum concentration of Dalfampridine can be increased when it is combined with Cisplatin.]
[A03AB15, diphemanil, The therapeutic efficacy of Diphemanil can be decreased when used in combination with Cisplatin.]
[A03AB09, isopropamide, The therapeutic efficacy of Isopropamide can be decreased when used in combination with Cisplatin.]
[S01FA03, methscopolamine, The therapeutic efficacy of Methscopolamine can be decreased when used in combination with Cisplatin.]
[N05CA07, talbutal, The therapeutic efficacy of Talbutal can be decreased when used in combination with Cisplatin.]
[P02CC01, pyrantel, Pyrantel may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J04AK01, pyrazinamide, Pyrazinamide may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J06BB05, rabies immune globulin, human, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Cisplatin.]
[P01AX05, quinacrine, The serum concentration of Cisplatin can be increased when it is combined with Quinacrine.]
[C01BA01, quinidine, The serum concentration of Cisplatin can be increased when it is combined with Quinidine.]
[P01BC01, quinine, The serum concentration of Cisplatin can be increased when it is combined with Quinine.]
[A02BA02, ranitidine, The serum concentration of Cisplatin can be increased when it is combined with Ranitidine.]
[C02AA02, reserpine, Reserpine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[J05AP01, ribavirin, Ribavirin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N02BA05, salicylamide, Salicylamide may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[A07EC01, sulfasalazine, The risk or severity of adverse effects can be increased when Cisplatin is combined with Sulfasalazine.]
[S01BC08, salicylic acid, Salicylic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[S01FA02, scopolamine, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Cisplatin.]
[N05CA06, secobarbital, Secobarbital may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N04BD01, selegiline, The metabolism of Selegiline can be decreased when combined with Cisplatin.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Cisplatin is combined with Obinutuzumab.]
[J01GB08, sisomicin, Cisplatin may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Sodium fluoride may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Cisplatin.]
[V04CC01, sorbitol, Sorbitol may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C07AA07, sotalol, Cisplatin may increase the bradycardic activities of Sotalol.]
[L01CD04, cabazitaxel, The risk or severity of adverse effects can be increased when Cisplatin is combined with Cabazitaxel.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cisplatin.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[V09AB03, ioflupane I-123, Ioflupane I-123 may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Technetium Tc-99m exametazime may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Florbetaben (18F) may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[V04CH02, indigo carmine, Indigotindisulfonic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N05CC01, chloral hydrate, Chloral hydrate may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N03AG01, valproic acid, The metabolism of Valproic acid can be decreased when combined with Cisplatin.]
[M05BA01, etidronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cisplatin is combined with Etidronic acid.]
[M05BA04, alendronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cisplatin is combined with Alendronic acid.]
[D07AB02, hydrocortisone butyrate, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Hydrocortisone butyrate.]
[L01CD03, paclitaxel poliglumex, The risk or severity of cardiotoxicity can be increased when Cisplatin is combined with Paclitaxel poliglumex.]
[D10AX03, azelaic acid, Azelaic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[R03BB01, ipratropium bromide, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Cisplatin.]
